ISN-ACT Clinical Trial List: July 2019
ISN Academy. ISN-ACT . Jul 10, 2019; 275275; 6197 Topic: Global Nephrology
Disclosure(s): The ISN-Advancing Clinical Trials is a new initiative of the ISN intended to leverage existing infrastructures within ISN, in order to improve global nephrology community participation in clinical trial research. As part of its activities, the ISN-ACT highlights and sometimes analyzes important recent nephrology trials from latest medical literature every month through the ISN-ACT Trial-list. Editors of the ISN-ACT Trial-List also select clinical trials of particular impact, and collaborate with the @ISNeducation social media learning team to represent these trials visually. Join the ISN-ACT To generate more high-quality clinical trials and studies in nephrology, ISN-ACT is calling on investigators and interested individuals. If you are an ISN member interested to join this great initiative, submit your application online. Use the button below (download PDF) to download this month's edition of the list.
Login now to access Regular content available to all registered users.

You may also access ISN content "anytime, anywhere" with the FREE ISN Academy App for iOS and Android.
Description
Discussion Forum (0)
Rate & Comment (0)
Once a month, the ISN-ACT (Advancing Clinical Trials) team collects and publishes a list of important nephrology trials from the latest medical literature. Each trial is reviewed in context and their risk of bias in seven key areas assessed.

This month, we reviewed the following trials:

- Polyhexanide: an alternative to iodine for PD catheter exit site care?
Effect of Local Polyhexanide Application in Preventing Exit-Site Infection and Peritonitis: A Randomized Controlled Trial
Ceri, et al. Ther Apher Dial. 2019 May 8. doi: 10.1111/1744-9987.12836.1283

- Roxadustat may be effectively dosed three times per week or weekly
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Akizawa, et al. Adv Ther. 2019;36(6):1438-1454

- CKD practice nurse and regular medical record audit does not affect progression of CKD in primary care
The Primary-Secondary Care Partnership to Improve Outcomes in Chronic Kidney Disease (PSP-CKD) Study: A Cluster Randomized Trial in Primary Care
Major, et al. J Am Soc Nephrol. 2019 May 16. doi: 10.1681/ASN.2018101042

- EPO post-transplant does not affect eGFR in pilot study
Treating Posttransplant Anemia With Erythropoietin Improves Quality of Life but Does Not Affect Progression of Chronic Kidney Disease
Pile, et al. Exp Clin Transplant. 2019 Jun 10. doi: 10.6002/ect.2018.0283

- Lower tacrolimus dosing feasible in low-risk Asian transplant recipients
Safety and Efficacy of Reduced Prolonged-release Tacrolimus Exposure in De Novo Kidney Transplantation: A Randomized, Open-label, Pilot Study in Asia-OPTIMIZE Study
Kim, et al. Transplant Direct. 2019 Mar 25;5(4):e340

- Longer courses of prednisolone might lower healthcare costs but do not affect relapse rate in childhood nephrotic syndrome.
Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. The PREDNOS trial
Webb et al. BMJ 2019;365:I1800

- Perindopril-amlodipine equal to perindopril-indapamide in pilot BP lowering study in Sub-Saharan diabetics
Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blinded randomised controlled trial
Sobngwi, et al. J Clin Hypertens (Greenwich). 2019 Jun 8. doi: 10.1111/jch.13557

A preview of this infographic is available below, and can be downloaded to the left.


 
Code of conduct/disclaimer available in General Terms & Conditions

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies